Sugi Predict

Sugi Predict / Compounds / SCHEMBL16741027

SCHEMBL16741027

SCHEMBL16741027

Cc1cnc(CO)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AGBL2 Q5U5Z8 2/20 0.37
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ NOS3 P29474 1/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ P2RX3 P56373 1/20 0.33
▸ P2RX2 Q9UBL9 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ CXCR4 P61073 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ ATM Q13315 1/20 0.32
▸ MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854474 0.84 AGBL2 (0.35) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL20261166 0.83 CCR1 (0.37) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL6935301 0.81 P2RX3 (0.35) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL4132951 0.81 NOS3 (0.35) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL25124308 0.80 LMNA (0.37) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL29636159 0.79 CCR1 (0.34) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL26971130 0.79 CHRM2 (0.35) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL16039165 0.79 CCR1 (0.34) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL13732029 0.79 NOS3 (0.39) AGBL2CCR1CCR5CCR8NOS3
SCHEMBL134813 0.78 AGBL2 (0.43) AGBL2DPP4MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 — — US disclosed
US-11987574-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2024-05-21 — — US disclosed
EP-4313970-A1 MK2 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-02-07 — — EP disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 — — US disclosed
CN-117120430-A MK2 inhibitors and uses thereof 新特拉有限公司 2023-11-24 — — CN disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 — — US disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 — — US disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 — — US disclosed
US-20230286950-A1 METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2023-09-14 — — US disclosed
US-20230265076-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-08-24 — — US disclosed
US-10189839-B2 Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase ACTELION PHARMACEUTICALS LTD (CH) 2019-01-29 — — US disclosed
EP-3071578-B1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2018-01-10 — — EP disclosed
US-9765092-B2 Tricyclic piperidine compounds ACTELION PHARMACEUTICALS LTD (CH) 2017-09-19 — — US disclosed
EP-3071567-B1 TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE ACTELION PHARMACEUTICALS LTD (CH) 2017-09-06 — — EP disclosed
US-20160289232-A1 TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE ACTELION PHARMACEUTICALS LTD (CH) 2016-10-06 — — US disclosed
EP-3071578-A1 TRICYCLIC PIPERIDINE COMPOUNDS Actelion Pharmaceuticals Ltd (CH) 2016-09-28 — — EP disclosed
EP-3071567-A1 TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE Actelion Pharmaceuticals Ltd (CH) 2016-09-28 — — EP disclosed
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2016-09-22 — — US disclosed
WO-2015075025-A1 TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE ACTELION PHARMACEUTICALS LTD (CH) 2015-05-28 — — WO disclosed
WO-2015075023-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987574-B2 MK2 inhibitors and uses thereof MKNK2, ENPP2, MAPKAPK2 AGBL2 839/4885CCR1 3969/4885CCR5 4234/4885
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF ENPP2, PLP2, PDXK AGBL2 1181/4885CCR1 3627/4885CCR5 3594/4885
US-10189839-B2 Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase TPH1, TPH2, MAOB AGBL2 2939/4885CCR1 2298/4885CCR5 3042/4885
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS TPH1, HTR1B, HTR1A AGBL2 4419/4885CCR1 395/4885CCR5 620/4885
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 AGBL2 839/4885CCR1 3969/4885CCR5 4234/4885
US-20230265076-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 AGBL2 839/4885CCR1 3969/4885CCR5 4234/4885
US-20160289232-A1 TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE TPH1, TPH2, MAOB AGBL2 2939/4885CCR1 2298/4885CCR5 3042/4885
US-20230286950-A1 METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS PDXK, DHPS, HCCS AGBL2 3121/4885CCR1 3357/4885CCR5 2719/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 AGBL2 1148/4885CCR1 125/4885CCR5 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.